ATR:NYE-AptarGroup Inc. (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 158.18

Change

0.00 (0.00)%

Market Cap

USD 4.78B

Volume

0.73M

Analyst Target

USD 125.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

AptarGroup, Inc., is a solution provider of packaging delivery solutions for the beauty, personal care, home care, prescription drug, consumer health care, injectables, food and beverage markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-22 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

-1.24 (-0.54%)

USD 66.03B
ALC Alcon AG

+0.62 (+0.73%)

USD 41.92B
RMD ResMed Inc

-6.10 (-2.57%)

USD 34.83B
BAX Baxter International Inc

-0.32 (-1.08%)

USD 16.24B
AVTR Avantor Inc

+0.05 (+0.24%)

USD 14.44B
TFX Teleflex Incorporated

+0.09 (+0.05%)

USD 8.27B
BLCO Bausch + Lomb Corp

-0.17 (-0.94%)

USD 7.27B
STVN Stevanato Group SpA

+0.46 (+2.24%)

USD 6.36B
WRBY Warby Parker Inc

-0.11 (-0.44%)

USD 2.84B
INFU InfuSystems Holdings Inc

-0.16 (-1.93%)

USD 0.18B

ETFs Containing ATR

NBSM Neuberger Berman ETF Trus.. 2.83 % 0.00 %

-0.01 (-0.04%)

USD 0.22B
XMLV Invesco S&P MidCap Low Vo.. 1.55 % 0.25 %

-0.41 (-0.04%)

USD 0.80B
FCUL:CA 0.00 % 0.00 %

N/A

N/A
TQSM:CA TD Q U.S. Small-Mid-Cap E.. 0.00 % 0.00 %

-0.01 (-0.04%)

CAD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 27.96% 79% B- 85% B
Dividend Return 1.39% 60% D- 23% F
Total Return 29.35% 79% B- 85% B
Trailing 12 Months  
Capital Gain 25.27% 79% B- 83% B
Dividend Return 1.36% 60% D- 22% F
Total Return 26.63% 79% B- 83% B
Trailing 5 Years  
Capital Gain 37.87% 75% C 70% C-
Dividend Return 6.76% 86% B+ 19% F
Total Return 44.64% 75% C 65% D
Average Annual (5 Year Horizon)  
Capital Gain 6.62% 58% F 56% F
Dividend Return 7.79% 58% F 53% F
Total Return 1.17% 60% D- 28% F
Risk Return Profile  
Volatility (Standard Deviation) 21.86% 74% C 50% F
Risk Adjusted Return 35.66% 89% A- 50% F
Market Capitalization 4.78B 64% D 87% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 24.10 82% 20%
Price/Book Ratio 4.49 36% 22%
Price / Cash Flow Ratio 19.80 36% 18%
Price/Free Cash Flow Ratio 16.52 62% 25%
Management Effectiveness  
Return on Equity 14.08% 92% 74%
Return on Invested Capital 9.39% 79% 65%
Return on Assets 7.01% 93% 86%
Debt to Equity Ratio 29.53% 60% 74%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector